Compare · ABT vs ME
ABT vs ME
Side-by-side comparison of Abbott Laboratories (ABT) and 23andMe Holding Co. (ME): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and ME operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $152.98B, about 78.8x ME ($1.94B).
- ABT has hit the wire 5 times in the past 4 weeks while ME has been quiet.
- ABT has more recent analyst coverage (25 ratings vs 8 for ME).
- Company
- Abbott Laboratories
- 23andMe Holding Co.
- Price
- $90.39+2.99%
- $0.60-21.02%
- Market cap
- $152.98B
- $1.94B
- 1M return
- +2.96%
- -
- 1Y return
- -32.16%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 5
- 0
- Recent ratings
- 25
- 8
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
23andMe Holding Co.
23andMe Holding Co. operates as a consumer genetics and research company. The company provides a crowdsourced platform for genetic research. Its platform has generated various publications on the genetic underpinnings of a range of diseases, conditions, and traits, as well as enables it in pursuing drug discovery programs rooted in human genetics across various disease areas, including oncology, respiratory, and cardiovascular diseases, as well as other therapeutic areas. The company was founded in 2006 and is based in Sunnyvale, California.
Latest ABT
- Director Stratton John G bought $173,640 worth of Common shares without par value (2,000 units at $86.82), increasing direct ownership by 9% to 23,319 units (SEC Form 4)
- SEC Form 11-K filed by Abbott Laboratories
- Abbott declares 410th consecutive quarterly dividend
- New research shows even stronger health outcomes for participants in a 'Food is Medicine' program when paired with support from community health workers
- New Abbott data show many people with diabetes may not recognize symptoms of diabetic ketoacidosis
- SEC Form SD filed by Abbott Laboratories
- Abbott secures CE Mark for world's first dual glucose-ketone sensing technology for people with diabetes
- ACS guideline reaffirms Abbott leadership in noninvasive colorectal cancer screening
- Abbott showcases expanding evidence across its cancer diagnostics portfolio at ASCO 2026
- SEC Form 4 filed by EXECUTIVE VICE PRESIDENT Moreland Mary K
Latest ME
- SEC Form 8-K filed by 23andMe Holding Co.
- 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law
- SEC Form 3 filed by new insider Kvarda Matthew
- SEC Form 3 filed by new insider Walper Thomas B.
- 23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure
- 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process
- 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test
- 23andMe Special Committee Rejects Acquisition Proposal From CEO Anne Wojcicki
- Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)
- SEC Form 10-Q filed by 23andMe Holding Co.